Heart Failure Outcomes With HIF-PHIs

This briefing examines whether hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs), compared with erythropoiesis-stimulating agents (ESAs), were associated with heart-failure hospitalization and related worsening-heart-failure outcomes in adults with heart failure and non-dialysis chronic kidney disease (CKD). The study focused on people who newly initiated either treatment while receiving ongoing diuretic therapy. [pmid:42666150]

Evidence

The reported design was a nationwide, retrospective, active-comparator cohort study using a Japanese claims database. Investigators identified heart failure before the index date through at least one recorded diagnosis code, ICD-10 I110 or I50, while excluding records flagged as “suspected.” ESAs were the active comparator. The cohorts included 14,995 HIF-PHI users and 22,889 ESA users; baseline characteristics were balanced with inverse probability of treatment weighting based on propensity scores. [pmid:42666150]

The primary outcome was heart failure hospitalization. Secondary outcomes included emergency heart failure hospitalization and hospitalization requiring intravenous diuretics. The investigators evaluated hazard ratios and 95% confidence intervals with Cox proportional hazards models and conducted predefined subgroup and sensitivity analyses. This design compares outcomes between newly treated groups in routine-care claims data, after measured baseline characteristics were balanced through weighting. [pmid:42666150]

For the primary outcome, the reported hazard ratio for heart failure hospitalization was 0.93 (95% CI, 0.87–1.01) for HIF-PHIs versus ESAs. The confidence interval includes 1.00, so this estimate does not establish a difference in the study’s primary hospitalization outcome. The study authors described HIF-PHIs as not associated with evidence of increased risk of heart failure hospitalization compared with ESAs. [pmid:42666150]

Hospitalization accompanied by intravenous diuretic administration was reported as significantly less frequent in the HIF-PHI cohort than in the ESA cohort. The reported hazard ratio for that outcome was 0.87 (95% CI, 0.81–0.94). Results were described as generally consistent across subgroup and sensitivity analyses, but that consistency does not remove the observational constraints of the underlying comparison. [pmid:42666150]

Analysis — Interpreting the Comparative Signal

The central result is a comparative association rather than a causal demonstration. The primary outcome estimate, 0.93 (95% CI, 0.87–1.01), is compatible with no difference in heart failure hospitalization between HIF-PHIs and ESAs because its confidence interval includes 1.00. Accordingly, the most supportable reading is limited: within this weighted claims-based cohort, the analysis did not show evidence that HIF-PHI initiation was associated with a higher hazard of the primary hospitalization outcome than ESA initiation. It should not be read as proof of equivalence, proof of safety in every setting, or evidence that individual patients will have a particular outcome. [pmid:42666150]

The intravenous-diuretic hospitalization result provides a second, more favorable comparative signal for HIF-PHIs, but it is a secondary outcome and should be kept distinct from the primary endpoint. Statistical significance for that secondary comparison does not itself establish clinical significance. The report also included emergency heart failure hospitalization among its secondary outcomes and stated that results were generally consistent across subgroup and sensitivity analyses. Those features strengthen the internal coherence of the reported findings, while still leaving interpretation anchored to the specific population, comparator, outcomes, and claims-data methods used here. [pmid:42666150]

The active-comparator, new-user framing and propensity-score IPTW balancing are important because they were intended to make the treatment groups more comparable on measured baseline characteristics. Yet weighting and Cox modeling address measured information available to the analysis; they cannot by themselves establish that every relevant difference between treatment groups was captured. The appropriate research conclusion is therefore narrow: the study contributes routine-practice comparative evidence relevant to heart failure and non-dialysis CKD, and its main result does not show an increased primary hospitalization association for HIF-PHIs relative to ESAs. [pmid:42666150]

Limitations

Residual confounding cannot be excluded because the study was observational. This limitation matters directly to causal interpretation: an observed association in a retrospective claims-based cohort may still reflect differences between groups that were not fully accounted for, even after IPTW balancing. [pmid:42666150]

The population was specifically adults with non-dialysis CKD and heart failure who initiated HIF-PHIs or ESAs during ongoing diuretic therapy. The findings therefore describe that defined treatment comparison and outcome framework; they should not be generalized beyond the study population or treated as patient-specific guidance. [pmid:42666150]